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Abstract: Background: We hypothesized that the change in stroke risk profile between baseline and
follow-up may be a better predictor of ischemic stroke than the baseline stroke risk determination using
the CHA2DS2-VASc score ((congestive heart failure, hypertension, age ≥75 years (doubled), diabetes,
stroke/transient ischemic attack/thromboembolism (doubled), vascular disease (prior myocardial
infarction, peripheral artery disease, or aortic plaque), age 65–75 years, sex category (female))).
Methods: We collected information for all patients treated with atrial fibrillation (AF) in French
hospitals between 2010 and 2019. We studied 608,108 patients with AF who did not have risk
factors of the CHA2DS2-VASc score (except for age and sex). The predictive accuracies of baseline
and follow-up CHA2DS2-VASc scores, as well as the ‘Delta CHA2DS2-VASc’ (i.e., change/difference
between the baseline and follow-up CHA2DS2-VASc scores) for prediction of ischemic stroke were
studied. Results: The mean CHA2DS2-VASc score at baseline was 1.7, and increased to 2.4 during
follow-up of 2.2 ± 2.4 years, (median (interquartile range: IQR) 1.2 (0.1–3.8) years), resulting in a mean
Delta CHA2DS2-VASc score of 0.7. Among 20,082 patients suffering ischemic stroke during follow-up,
67.1% had a Delta CHA2DS2-VASc score ≥1 while they were only 40.4% in patients without ischemic
stroke. The follow-up CHA2DS2-VASc score and Delta CHA2DS2-VASc score were predictors of
ischemic stroke (C-index 0.670, 95% confidence interval (CI) 0.666–0.673 and 0.637, 95%CI 0.633–0.640)
and they performed better than baseline CHA2DS2-VASc score (C-index 0.612, 95%CI 0.608–0.615,
p < 0.0001). Conclusions: Stroke risk was non-static, and many AF patients had ≥1 new stroke
risk factor(s) before ischemic stroke occurred. The follow-up CHA2DS2-VASc score and its change
(i.e., ‘Delta CHA2DS2-VASc’) were better predictors of ischemic stroke than relying on the baseline
CHA2DS2-VASc score.
Keywords: atrial fibrillation; ischemic stroke; risk evaluation
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1. Introduction
The presence of atrial fibrillation (AF) is a recognized risk factor for ischemic stroke [1]. In these
patients, the use of oral anticoagulation reduces the risk of ischemic stroke and mortality in clinical
trials or observational cohorts [1].
The CHA2DS2-VASc score is calculated using the baseline risk factors for assessment of the risk
of ischemic stroke risk in patients with AF [2]. However, the stroke risk in patients with AF is not
static, and with time, patients get older and acquire new comorbidities. Indeed, one analysis from
Taiwan reported that the change in CHA2DS2-VASc score between baseline and follow-up was a better
predictor of ischemic stroke [3]. A similar observation was reported from Korea [4]. We are unaware of
any similar studies in white European cohort.
We analyzed a nationwide cohort from France and we hypothesized that the change in stroke risk
profile between baseline and follow-up may be a better predictor of ischemic stroke than the baseline
stroke risk determination using the CHA2DS2-VASc score.
2. Methods
Our nationwide French longitudinal cohort study used the national database covering hospital
care for the whole population. The data for all patients admitted with AF in France from January 2010
to December 2018 were collected from the national administrative database, the PMSI (Programme
de Médicalisation des Systeèmes d’Information). This includes around 98% of the French population
(67 million people) from birth (or immigration) to death (or emigration). As a result of this program
implemented in 2004, medical activity is recorded in a database, computed, and rendered anonymous
in the 1546 French healthcare facilities. Medical information includes the principal and secondary
diagnoses which are identified with codes according to the International Classification of Diseases
(ICD-10). Data for medical procedures were collected with the CCAM (classification commune des
actes médicaux) which is the French medical reimbursement classification for clinical procedures. The
PMSI contains individual pseudo anonymized information on each hospitalization that are linked to
create a longitudinal record of hospital stays and diagnoses for each patient. Its reliability has been
well evaluated [5] and this database has been used to study subjects with cardiovascular conditions,
including those with AF or ischemic stroke [6–8]
This type of study was approved by our local institutional review board, on 1 December 2015
and was registered as a clinical audit. Ethical review was consequently not needed. The study was
conducted retrospectively, patients were not involved in its conduct, and there was no impact on
their care. Procedures for data collection and management have been approved by the Commission
Nationale de l’Informatique et des Libertés (CNIL), the independent National ethical committee in
France ensuring that information is kept confidential and anonymous (authorization number 1897139).
2.1. Study Population
We identified all patients over 18 years in the period from 1 January, 2010 to 31 December, 2018
hospitalized with a diagnosis of AF (I48 and its subsections using ICD10 codes) over the study period.
The study database was constructed using the encrypted anonymized number. Patient information
(including medical history and events of interest during follow-up) was described using data collected
in the hospital records. Diagnoses were obtained for each hospital stay at discharge. For the present
analysis, follow-up started at the date of AF diagnosis. We calculated the CHA2DS2-VASc score
for every patient. In this population, there were 608,108 patients not having any risk factors of the
CHA2DS2-VASc score, except for age and sex; and this was the population of interest for our study.
During a follow-up of 1,322,449 person-years, 20,082 patients suffered ischemic stroke (incidence rate
1.52%/year). The flowchart of patients enrolled in the study is shown in Figure 1.
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Figure 1. Flowchart of the study population. CHA2DS2-VASc score: (congestive heart failure, 
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age 65–75 years, sex category (female)). 
2.2. Baseline, Follow-Up, Delta CHA2DS2-VASc Scores, and Its Slope 
The CHA2DS2-VASc scores were determined at baseline for all patients at study entry (baseline 
CHA2DS2-VASc score). The CHA2DS2-VASc scores at follow-up were defined as the highest recorded 
CHA2DS2-VASc score of each patient during the follow-up period, before the occurrence of ischemic 
stroke, mortality, and/or at the last news for patients free of these events. The Delta CHA2DS2-VASc 
score was defined as the difference between the baseline and follow-up scores (follow-up CHA2DS2-
VASc minus baseline CHA2DS2-VASc scores). Among patients with a Delta CHA2DS2-VASc score ≥ 1, the 
rate of change in scores was also assessed by calculating the slope. The slope of CHA2DS2-VASc score 
change was defined as the following: log ((Delta CHA2DS2-VASc score/follow-up duration (duration 
in years between the index date and the date when the highest CHA2DS2-VASc score was 
recorded))+1). 
2.3. Statistical Analyses 
Qualitative variables are described using counts and percentages and continuous quantitative 
variables as means ± standard deviation and also median and quartiles when necessary. Comparisons 
between groups were made with chi-square tests for comparing categorical variables and the Student 
t test or non-parametric Kruskal–Wallis test where appropriate for continuous variables. Information 
on outcomes during follow-up was obtained by analyzing the PMSI codes for each patient. For the 
outcomes analysis, the incidence rates (%/year) was estimated in the different groups. The diagnostic 
accuracies of baseline, follow-up, and Delta CHA2DS2-VASc scores in predicting ischemic stroke were 
assessed by calculating C-indexes. The areas under the receiver-operating characteristic (ROC) curves 
(AUCs) of these scorings were compared using the DeLong test. Net reclassification improvement 
(NRI) and decision-curve analysis (DCA) were used to estimate the clinical usefulness of the 
predictive models. In all analyses, a p value < 0.05 was considered statistically significant. All analyses 
were performed using Enterprise Guide ® 7.1, ©SAS Institute (SAS Campus Drive, Cary, NC, USA) 
and STATA® 12, (©Stata Corp, College Station, TX, USA).  
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(doubled), vascular disease (pri r myocardial infarction, peripheral artery dise se, o aortic plaque),
age 65–75 year , sex category (female)).
2.2. Baseline, Follow-Up, Delta CHA2DS2-VASc Scores, and Its Slope
The CHA2DS2-VASc scores were determined at baseline for all patients at study entry (baseline
CHA2DS2-VASc score). The CHA2DS2-VASc scores at follow-up were defined as the highest recorded
CHA2DS2-VASc score of each patient during the follow-up period, before the occurrence of ischemic
stroke, mortality, and/or at the last news for patients free of these events. The Delta CHA2DS2-VASc score
was defined as the difference between the baseline and follow-up scores (follow-up CHA2DS2-VASc
minus baseline CHA2DS2-VASc scores). Among patients with a Delta CHA2DS2-VASc score ≥ 1, the
rate of change in scores was also assessed by calculating the slope. The slope of CHA2DS2-VASc score
change was defined as the following: log ((Delta CHA2DS2-VASc score/follow-up duration (duration in
years bet een the index date and the date when the highest CHA2DS2-VASc score was recorded))+1).
2.3. Statistical Analyses
Qualitative variables are described using counts and percentages and continuous quantitative
variables as mea s ± standard deviation and also median and quartiles when necessary. Comparisons
between groups were made with chi-square tests for comparing categorical variables and the Student t
test or non-parametric Kruskal–Wallis test where appropriate for continuous variables. Information
on outcomes during follow-up was obtained by analyzing the PMSI codes for each patient. For the
outcomes analysis, the incidence rates (%/year) was estimated in the different groups. The diagnostic
accuracies of baseline, follow-up, and Delta CHA2DS2-VASc scores in predicting ischemic stroke were
assessed by calculating C-indexes. The areas under the receiver-operating characteristic (ROC) curves
(AUCs) of these scorings were compared using the DeLong test. Net reclassification improvement
(NRI) and decision-curve analysis (DCA) were used to estimate the clinical usefulness of the predictive
models. In all analyses, a p value < 0.05 was considered statistically significant. All analyses were
performed using Enterprise Guide ® 7.1, ©SAS Institute (SAS Campus Drive, Cary, NC, USA) and
STATA® 12, (©Stata Corp, College Station, TX, USA).
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2.4. Data Access
Because this study used data from human subjects, the data and everything pertaining to the data
are governed by the French Health Agencies and cannot be made available to other researchers.
3. Results
The characteristics of patients with or without ischemic stroke are in Table 1. Age increased
from 72.7 to 74.8 years during a mean follow-up of 2.2 ± 2.4 years (median (interquartile range:
IQR) 1.2 (0.1–3.8)). The mean of the baseline CHA2DS2-VASc score was 1.7, and it increased to 2.4
during follow-up, with a mean Delta CHA2DS2-VASc score of 0.7. The baseline, follow-up and Delta
CHA2DS2-VASc scores were higher for patients suffering ischemic stroke than those with no stroke
(Figure 2). The % of patients with a Delta CHA2DS2-VASc score = 0 was 58.8%, meaning that more
than 40% of patients had more comorbidities or became >65 or 75 years during follow-up. Around 38%
of patients had ≥1 new-onset comorbidity, the most frequent being hypertension (25.7%) and heart
failure (20.7%).
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Figure 2. CHA2DS2-VASc scores of patients with AF with or without ischemic stroke: baseline,
follow-up, and Delta CHA2DS2-VASc scores (top panel) and repartition of Delta CHA2DS2-VASc
in these patients (lower panel). CHA2DS2-VASc score: (congestive heart failure, hypertension, age
≥75 years (doubled), diabetes, stroke/transient ischemic attack/thromboembolism (doubled), vascular
disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), age 65–75 years, sex
category (female)).
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Table 1. Baseline characteristics of AF patients.
Total No IschemicStroke Ischemic Stroke p
(n = 608108) (n = 588026) (n = 20082)
Characteristics at baseline
Age, years 72.7 ± 14.6 72.5 ± 14.6 78.3 ± 10.8 <0.0001
Age 65–74 yrs 135994 (22.4) 132380 (22.5) 3614 (18.0) <0.0001
Age ≥75 yrs 313332 (51.5) 299213 (50.9) 14119 (70.3) <0.0001
Gender (male) 341299 (56.1) 331608 (56.4) 9691 (48.3) <0.0001
CHA2DS2-VASc score 1.7 ± 1.1 1.7 ± 1.1 2.1 ± 0.9 <0.0001
CHA2DS2-VASc score = 0 110373 (18.2) 108728 (18.5) 1645 (8.2) <0.0001
CHA2DS2-VASc score = 1 131674 (21.7) 128849 (21.9) 2825 (14.1) <0.0001
CHA2DS2-VASc score = 2 197673 (32.5) 190410 (32.4) 7263 (36.2) <0.0001
CHA2DS2-VASc score = 3 168388 (27.7) 160039 (27.2) 8349 (41.6) <0.0001
Coronary artery disease 52807 (8.7) 50744 (8.6) 2063 (10.3) <0.0001
Previous pacemaker or
Defibrillator 8317 (1.4) 8022 (1.4) 295 (1.5) 0.21
Smoker 26202 (4.3) 25687 (4.4) 515 (2.6) <0.0001
Dyslipidemia 38136 (6.3) 36967 (6.3) 1169 (5.8) 0.01
Obesity 33410 (5.5) 32700 (5.6) 710 (3.5) <0.0001
Alcohol related diagnoses 24514 (4.0) 23803 (4.0) 711 (3.5) 0.0003
Abnormal renal function 10898 (1.8) 10555 (1.8) 343 (1.7) 0.36
Lung disease 60242 (9.9) 58721 (10.0) 1521 (7.6) <0.0001
Liver disease 13894 (2.3) 13572 (2.3) 322 (1.6) <0.0001
Thyroid diseases 39551 (6.5) 38244 (6.5) 1307 (6.5) 0.98
Inflammatory disease 22307 (3.7) 21587 (3.7) 720 (3.6) 0.52
Anemia 54504 (9.0) 52925 (9.0) 1579 (7.9) <0.0001
Previous cancer 93633 (15.4) 91466 (15.6) 2167 (10.8) <0.0001
Characteristics after the
follow-up
Age, years 74.8 ± 14.6 74.6 ± 14.7 80.8 ± 10.8 <0.0001
Age 65–74 yrs 128281 (21.1) 125254 (21.3) 3027 (15.1) <0.0001
Age ≥75 yrs 343328 (56.5) 328135 (55.8) 15193 (75.7) <0.0001
CHA2DS2-VASc score 2.4 ± 1.5 2.3 ± 1.5 3.2 ± 1.3 <0.0001
CHA2DS2-VASc score = 0 76845 (12.6) 76186 (13.0) 659 (3.3) <0.0001
CHA2DS2-VASc score = 1 100752 (16.6) 99369 (16.9) 1383 (6.9) <0.0001
CHA2DS2-VASc score = 2 144335 (23.7) 140771 (23.9) 3564 (17.7) <0.0001
CHA2DS2-VASc score = 3 160270 (26.4) 154124 (26.2) 6146 (30.6) <0.0001
CHA2DS2-VASc score = 4 78774 (13.0) 73630 (12.5) 5144 (25.6) <0.0001
CHA2DS2-VASc score = 5 37770 (6.2) 35291 (6.0) 2479 (12.3) <0.0001
CHA2DS2-VASc score = 6 8584 (1.4) 7941 (1.4) 643 (3.2) <0.0001
CHA2DS2-VASc score = 7 778 (0.1) 714 (0.1) 64 (0.3) <0.0001
New-onset comorbidities
Hypertension 156081 (25.7) 146131 (24.9) 9950 (49.5) <0.0001
Heart failure 125684 (20.7) 119795 (20.4) 5889 (29.3) <0.0001
Diabetes mellitus 27105 (4.5) 25531 (4.3) 1574 (7.8) <0.0001
Vascular disease 40512 (6.7) 37503 (6.4) 3009 (15.0) <0.0001
Any new-onset comorbidity 227993 (37.5) 214952 (36.6) 13041 (64.9) <0.0001
Delta CHA2DS2-VASc score 0.7 ± 0.9 0.6 ± 0.9 1.1 ± 1.0 <0.0001
Delta CHA2DS2-VASc score = 0 357349 (58.8) 350738 (59.6) 6611 (32.9) <0.0001
Delta CHA2DS2-VASc score = 1 140768 (23.1) 133503 (22.7) 7265 (36.2) <0.0001
Delta CHA2DS2-VASc score = 2 76373 (12.6) 72090 (12.3) 4283 (21.3) <0.0001
Delta CHA2DS2-VASc score = 3 27067 (4.5) 25498 (4.3) 1569 (7.8) <0.0001
Delta CHA2DS2-VASc score = 4 5809 (1.0) 5484 (0.9) 325 (1.6) <0.0001
Delta CHA2DS2-VASc score = 5 742 (0.1) 713 (0.1) 29 (0.1) 0.36
Values are mean ± SD or n (%). AF = atrial fibrillation; CHA2DS2-VASc = congestive heart failure, hypertension,
age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65–74 years, sex
category (female).
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Among 20,082 patients who suffered ischemic stroke, 67.1% had a Delta CHA2DS2-VASc score
≥1 compared while this was the case for only 40.4% in patients with no ischemic stroke (Figure 2),
and 13,041 (64.9%) patients were identified as having ≥1 new-onset comorbidity (hypertension in 9950
(49.5%), heart failure in 5889 (29.3%), diabetes mellitus in 1574 (7.8%), and vascular diseases in 3009
(15.0%)) (Table 1). In patients who experienced ischemic stroke, the number of new-onset comorbidities
is shown in Supplemental Figure S1. This shows that 53.9% of patients developed 1 new comorbidity,
whilst 2, 3, and 4 new comorbidities were identified in 31.8%, 11.6%, and 2.6% of patients.
3.1. Baseline, Follow-Up and Delta CHA2DS2-VASc Scores, and the Risk of Ischemic Stroke
The characteristics of patients by the Delta CHA2DS2-VASc score are in Table 2. The yearly risk of
ischemic stroke increased continuously from 0.67% for those patients with a baseline CHA2DS2-VASc
score = 0 to 2.52% for those with a baseline CHA2DS2-VASc score = 3, and from 0.60% for those with a
follow-up CHA2DS2-VASc score = 0 to 1.98% for patients with a follow-up CHA2DS2-VASc score = 4
(Table 3). Considering Delta CHA2DS2-VASc score, the highest risk was seen for patients with a Delta
CHA2DS2-VASc score = 1.
Table 2. Characteristics of patients with AF stratified by delta CHA2DS2-VASc score.
Delta
CHA2DS2-VASc score = 0
Delta
CHA2DS2-VASc score = 1
Delta
CHA2DS2-VASc score = 2
Delta
CHA2DS2-VASc score ≥3
(n = 357349) (n = 140768) (n = 76373) (n = 33618)
Characteristics at baseline
Age, years 70.7 ± 16.1 75.1 ± 12.2 76.7 ± 10.8 74.6 ± 9.6
Age 65–74 yrs 75426 (21.1) 31574 (22.4) 17578 (23.0) 11416 (34.0)
Age ≥75 yrs 171231 (47.9) 79587 (56.5) 46575 (61.0) 15939 (47.4)
Gender (male) 200713 (56.2) 77384 (55.0) 41750 (54.7) 21452 (63.8)
CHA2DS2-VASc score 1.6 ± 1.1 1.8 ± 1.0 1.9 ± 1.0 1.6 ± 1.0
CHA2DS2-VASc score = 0 76841 (21.5) 20344 (14.5) 8444 (11.1) 4607 (13.7)
CHA2DS2-VASc score = 1 79937 (22.4) 28338 (20.1) 14311 (18.7) 9081 (27.0)
CHA2DS2-VASc score = 2 107111 (30.0) 49157 (34.9) 28689 (37.6) 12829 (38.2)
CHA2DS2-VASc score = 3 93460 (26.2) 42929 (30.5) 24929 (32.6) 7101 (21.1)
Coronary artery disease 18290 (5.1) 17106 (12.2) 10545 (13.8) 6866 (20.4)
Previous pacemaker or
Defibrillator 4331 (1.2) 2237 (1.6) 1244 (1.6) 505 (1.5)
Smoker 17859 (5.0) 5074 (3.6) 2231 (2.9) 1038 (3.1)
Dyslipidemia 21218 (5.9) 9811 (7.0) 4929 (6.5) 2178 (6.5)
Obesity 19348 (5.4) 7493 (5.3) 4323 (5.7) 2246 (6.7)
Alcohol related diagnoses 15704 (4.4) 5050 (3.6) 2492 (3.3) 1268 (3.8)
Abnormal renal function 5846 (1.6) 2733 (1.9) 1585 (2.1) 734 (2.2)
Lung disease 35331 (9.9) 13682 (9.7) 7692 (10.1) 3537 (10.5)
Liver disease 8938 (2.5) 2956 (2.1) 1407 (1.8) 593 (1.8)
Thyroid diseases 23446 (6.6) 9591 (6.8) 4866 (6.4) 1648 (4.9)
Inflammatory disease 13299 (3.7) 5104 (3.6) 2773 (3.6) 1131 (3.4)
Anemia 34058 (9.5) 12223 (8.7) 6011 (7.9) 2212 (6.6)
Previous cancer 61422 (17.2) 20163 (14.3) 8798 (11.5) 3250 (9.7)
Characteristics after the
follow-up
Follow-up duration (years) 1.2 ± 1.9 3.0 ± 2.4 3.8 ± 2.4 4.8 ± 2.3
Age, years 71.9 ± 15.9 78.1 ± 11.9 80.5 ± 10.4 79.3 ± 9.2
Age 65–74 yrs 75426 (21.1) 31250 (22.2) 14225 (18.6) 7380 (22.0)
Age ≥75 yrs 171231 (47.9) 91132 (64.7) 56420 (73.9) 24545 (73.0)
CHA2DS2-VASc score 1.6 ± 1.1 2.8 ± 1.0 3.9±1.0 4.9 ± 1.0
CHA2DS2-VASc score = 0 76845 (21.5) 0 (0.0) 0 (0.0) 0 (0.0)
CHA2DS2-VASc score = 1 79940 (22.4) 20812 (14.8) 0 (0.0) 0 (0.0)
CHA2DS2-VASc score = 2 107108 (30.0) 28419 (20.2) 8808 (11.5) 0 (0.0)
CHA2DS2-VASc score = 3 93456 (26.2) 48898 (34.7) 14432 (18.9) 3484 (10.4)
CHA2DS2-VASc score = 4 0 (0.0) 42639 (30.3) 28480 (37.3) 7655 (22.8)
CHA2DS2-VASc score = 5 0 (0.0) 0 (0.0) 24653 (32.3) 13117 (39.0)
CHA2DS2-VASc score = 6 0 (0.0) 0 (0.0) 0 (0.0) 8584 (25.5)
CHA2DS2-VASc score = 7 0 (0.0) 0 (0.0) 0 (0.0) 778 (2.3)
Hypertension 0 (0.0) 61486 (43.7) 62627 (82.0) 31968 (95.1)
Heart failure 0 (0.0) 45143 (32.1) 51028 (66.8) 29513 (87.8)
Diabetes mellitus 0 (0.0) 4590 (3.3) 9115 (11.9) 13400 (39.9)
Vascular disease 0 (0.0) 6783 (4.8) 13639 (17.9) 20090 (59.8)
Any new-onset comorbidity 0 (0.0) 118002 (83.8) 76373 (100.0) 33618 (100.0)
Values are mean ± SD or n (%). Abbreviation as in Table 1. IQR = interquartile range.
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Table 3. Risk of ischemic stroke in AF patients with different baseline follow-up and delta
CHA2DS2-VASc score (mean (SD) 2.2 (2.4), median (IQR) 1.2 (0.1–3.8) years).
Number of
Patients
Number of
Incident Ischemic
Stroke
Incidence of
Ischemic Stroke
(%/year)
Hazard. Ratio
(95%CI) p
Baseline CHA2DS2-VASc score
0 (reference
group) 111,269 1687 0.67 1.00
1 131,937 2852 0.91 1.35 (1.27–1.43) <0.0001
2 197,176 7238 1.69 2.54 (2.41–2.68) <0.0001
3 167,726 8305 2.52 3.80 (3.61–4.01) <0.0001
Follow-up CHA2DS2-VASc score
0 (reference
group) 76,845 659 0.60 1.00
1 100,752 1383 0.77 1.30 (1.18–1.42) <0.0001
2 144,335 3564 1.34 2.25 (2.07–2.44) <0.0001
3 160,270 6146 1.91 3.20 (2.95–3.47) <0.0001
4 78,774 5144 1.98 3.38 (3.12–3.67) <0.0001
≥5 47,132 3186 1.70 2.90 (2.66–3.15) <0.0001
Delta CHA2DS2-VASc score
0 (reference
group) 357,349 6611 1.50 1.00
1 140,768 7265 1.69 1.16 (1.12–1.20) <0.0001
2 76,373 4283 1.46 0.99 (0.96–1.03) 0.75
3 27,067 1569 1.27 0.85 (0.81–0.90) <0.0001
≥4 6551 354 0.99 0.65 (0.58–0.72) <0.0001
Values are n (incidence rate, %/year); CI = confidence interval. AF = atrial fibrillation; SD = standard deviation;
IQR = interquartile range.
When considering the baseline, follow-up and delta CHA2DS2-VASc scores, using their respective
score = 0 as the reference, the hazard ratios for the strata of the increasing scores are in Table 3.
Increasing baseline and follow-up CHA2DS2-VASc scores were associated with a higher risk of ischemic
stroke. This was also the case for subjects with delta CHA2DS2-VASc score of 1 (compared to 0 as the
reference), but this association was not seen when Delta CHA2DS2-VASc score got higher.
Figure 3 presents the AUC for the baseline, follow-up, and Delta CHA2DS2-VASc scores for
prediction of ischemic stroke. The AUC was lower for the baseline CHA2DS2-VASc score (0.612, 95%CI
0.608–0.615) compared to that of follow-up (0.670, 95%CI 0.666–0.673) or Delta (0.637, 95%CI 633–640)
scores (p < 0.0001 for DeLong test).
When we used NRI, we found a significant difference in the follow-up score compared to
the baseline score, NRI being 14.4% (95% CI: 13.5 to 15.4%; p < 0.0001). Considering the Delta
CHA2DS2-VASc score versus baseline score, the NRI was 14.4% (95% CI: 13.5 to 15.4%; p < 0.0001).
Regarding the follow-up score vs the Delta score, NRI was 7.5% (95% CI: 6.5% to 8.4%; p < 0.0001).
Using DCA, assuming that a high risk identified by one of the tests would result in different treatment,
FU CHA2DS2-VASc score was superior to the “treat all” strategy and the “treat none” strategy. The FU
CHA2DS2-VASc score was likewise superior to the CHA2DS2-VASc score and Delta CHA2DS2-VASc
score for any threshold probability (Figure 3).
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3.2. Slope of the Change in CHA2DS2-VASc Score
The slope was higher for patients with ischemic stroke than in those with no ischemic stroke (0.9
vs. 0.7; p < 0.0001), and this was also seen with different Delta CHA2DS2-VASc score (Table 4). The
OR for suffering ischemic stroke was 1.29 (95% CI: 1.27 to 1.31; p < 0.0001) per 1 unit of the slope for
patients with a Delta CHA2DS2-VASc score ≥1. This increased from 1.22 (95% CI: 1.19 to 1.24) for
patients with a Delta CHA2DS2-VASc score = 1 to 1.64 (95% CI: 1.37 to 1.96) for patients with a Delta
CHA2DS2-VASc score ≥4. The AUCs of the slope for prediction of ischemic stroke were marginally
higher for patients with higher Delta CHA2DS2-VASc scores (2 and ≥3) than for those with lower Delta
CHA2DS2-VASc score = 1 (Supplemental Figure S2).
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Table 4. Slope of the change of c CHA2DS2-VASc score and the risk of ischemic stroke in each group of
delta CHA2DS2-VASc score.
No
Ischemic
Stroke
Ischemic
Stroke p value
Odds Ratio (95% CI) of
Ischemic Stroke Per
Unit Slope Change
p value
(n = 237288) (n = 13471)
Delta CHA2DS2-VASc
Score
All (≥1) 0.7 ± 0.8 0.9 ± 1.2 <0.0001 1.29 (1.27–1.31) <0.0001
1 0.7 ± 0.9 0.9 ± 1.3 <0.0001 1.22 (1.19–1.24) <0.0001
2 0.7 ± 0.6 0.9 ± 1.2 <0.0001 1.48 (1.44–1.53) <0.0001
3 0.7 ± 0.5 0.9 ± 0.9 <0.0001 1.54 (1.44–1.64) <0.0001
≥ 4 0.6 ± 0.4 0.8 ± 0.8 <0.0001 1.64 (1.37–1.96) <0.0001
4. Discussion
In this study from a white European nationwide AF cohort, our main findings are: (1) Stroke
risk (assessed by CHA2DS2-VASc score) was non-static, and many patients developed ≥1 new
stroke risk factor(s) before presenting with ischemic stroke; and (2) the follow-up CHA2DS2-VASc
score and its evolution (i.e.,‘Delta CHA2DS2-VASc’, reflecting the modification in stroke risk profile
between baseline and follow-up) were better predictors of ischemic stroke than relying on the baseline
CHA2DS2-VASc score.
To our knowledge, this is the first report assessing the dynamic nature of stroke risk in a non-Asian
cohort, using a large dataset from the large France nationwide administrative hospital-discharge
database. The present study from France is the first from a non-Asian cohort, and was substantially
larger than either the Taiwan and South Korea studies. In contrast to prior studies, we found that the
follow-up CHA2DS2-VASc score had the best value for predicting ischemic stroke, as shown by AUCs
and NRI.
In the study from Taiwan, Chao et al [3] reported that among AF patients with ischemic stroke,
89% had a Delta CHA2DS2-VASc score ≥1 whereas this was the case for only 55% in patients without
ischemic stroke, and 64% patients had≥1 new-onset comorbidity, the most common being hypertension.
The Delta CHA2DS2-VASc score was a significant predictor of ischemic stroke performing better than
baseline or follow-up CHA2DS2-VASc scores.
By contrast to the follow-up CHA2DS2-VASc score, an increasing Delta CHA2DS2-VASc score
above 1 (2, 3, and ≥4) in our study was not significantly associated with a higher risk of ischemic stroke.
This may seem counterintuitive and different to Chao et al [3], but our patients with highest Delta
CHA2DS2-VASc in our study had longer follow-up, lower prevalence of those age above 75 and lower
baseline CHA2DS2-VASc score. This may partly explain why the univariate analysis by strata of the
Delta CHA2DS2-VASc score did not find increasing risk when Delta CHA2DS2-VASc score increased
above 2. Of note, the predictive value of the slope of CHA2DS2-VASc score change in the different
strata confirms that the increasing number of risk factors per year provides consistent evidence on the
increasing risk of stroke in our population.
In a similar analysis in Korea, studying more than 160,000 AF patients with no anticoagulation,
Yoon et al [4] reported that during follow-up of 10 years, the rate of ischemic stroke was higher when
patients had incident risk factors, and were re-classified into categories with higher CHA2DS2-VASc
score. Thus, the two Asian study and our results reaffirm why assessment of stroke risk is needed at
each contact with the patient, as addition of risk factors and increasing CHA2DS2-VASc score results
over time in a greater stroke risks. Of note, the dynamic nature of risk is not only evident for stroke
risk, but also for bleeding risk. Chao et al also showed that the best predictive value for major bleeding
was the follow-up and change HAS-BLED score [9,10].
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Assessment of clinical usefulness (using Decision Curve Analysis) re-emphasizes the value of
follow-up stroke risk assessment. When assessing the slope of change in CHA2DS2-VASc scores, the
predictive value was better for patients when they had higher Delta CHA2DS2-VASc scores (2 and
≥3) compared to those who had a lower Delta CHA2DS2-VASc score of 1. Indeed, the “take home”
message should be that clinicians should not rely on baseline ’one off’ stroke risk assessment, but
regular re-assessment, for the follow-up or change in stroke risk profile, which is a better predictor
compared to the baseline assessment.
Limitations
One limitation of this study was related to its observational and retrospective nature. This analysis
is limited by its registry design, and errors for classification or coding may be present. Identifying AF
and comorbidities is challenging. However, ICD-10 is considered reliable for identifying AF, stroke
and stroke risk factors [11–13]. The PMSI was previously verified and used for epidemiologic purpose
in AF patients or those with ischemic stroke [7]. We were not able to differentiate paroxysmal AF from
persistent and permanent AF, whereas patients with permanent AF may have a higher risk of stroke.
Events included were only in-hospital, and we had no outpatient data. Results apply to inpatients
with AF and may not apply to all AF patients. Data were based on the diagnostic codes registered for
reimbursement purposes and were not externally checked with a potential information bias. However,
our study aimed to provide a simple clinical approach and a global picture at a national level not
limited to tertiary referral centers. Drug therapies, particularly oral anticoagulation use, were not
included in the analysis, which may impact on event rates at follow-up. The recent EORP-AF registry
indicates that the rate of anticoagulation therapy based on CHA2DS2VASc score (≥2) in Europe is
generally above 85% [14] and this should apply to our nationwide analysis. Another limitation is
the lack of available information concerning time in therapeutic range for international normalized
ratios for patients taking vitamin K antagonist. However, the study size of the population including
every hospitalization in France with a negligible risk of follow-up loss may compensate for some of
these limitations.
5. Conclusions
Stroke risk (CHA2DS2-VASc score) was dynamic, and many AF patients had ≥1 new stroke
risk factor(s) before they suffered ischemic stroke. The follow-up CHA2DS2-VASc score and its
change (i.e., Delta CHA2DS2-VASc, picturing the evolution in stroke risk profile between baseline
and follow-up) were better predictors of ischemic stroke than relying on the baseline CHA2DS2-VASc
score. This emphasizes that stroke risk in AF is an evolving process when age increases and when new
comorbidities appear, and regular re-assessment of risk is needed.
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